How to Spot Biotech Manufacturing Risk Before the FDA Does

You bought a gene therapy stock two weeks before its PDUFA date. The Phase 3 data was clean, the advisory committee voted your way, and every analyst note said approval was a formality. Then the FDA issued a Complete Response Letter, not because the data failed, but because the manufacturing process wasn’t consistent. The stock dropped 40% in a day, and you never saw it coming because you never checked the factory.

That is the most frustrating loss in biotech. A CRL (Complete Response Letter) is the FDA’s formal rejection of a drug application, and it is not always about the science. Between 2018 and 2022, about 37% of new drug applications received one. A meaningful share of those were CMC failures, meaning chemistry, manufacturing, and controls problems, not efficacy or safety problems. The drug works. The factory doesn’t.

The fix is a three-question checklist you run before every FDA catalyst trade: Is this a biologic or a small molecule? Has the FDA inspected the facility, and what did it find? And has the company disclosed manufacturing problems in its SEC filings?

Step 1: Know if it’s an NDA or a BLA

Small-molecule drugs (pills, like most kinase inhibitors) are filed as an NDA (New Drug Application). Biologics (antibodies, gene therapies, cell therapies, vaccines) are filed as a BLA (Biologics License Application).

The distinction matters because biologics carry far more manufacturing risk. A small molecule is synthesized through predictable chemistry. A biologic is grown inside living cells, and every batch is slightly different. That batch-to-batch variability is why BLAs get more manufacturing CRLs than NDAs. If you are trading a gene therapy or cell therapy PDUFA, manufacturing is a first-order risk, not a footnote. Start with the BLA vs NDA breakdown to classify your trade.

Step 2: Find the inspection status

Every new drug application faces a pre-approval inspection (PAI), where FDA investigators walk the manufacturing facility to confirm it can actually make the product at commercial scale. PAIs typically happen two to six months before the PDUFA date.

The inspection result is public. Search the FDA Data Dashboard for the facility and read the classification: NAI (No Action Indicated, clean), VAI (Voluntary Action Indicated, problems found but fixable), or OAI (Official Action Indicated, serious, often a rejection signal). Do not be fooled by the word “voluntary.” VAI still means the FDA found problems. OAI on a facility making your drug is a red flag worth acting on.

Step 3: Check for Form 483s and warning letters

A Form 483 is the list of objectionable conditions an inspector writes up at the end of an inspection. It is not a final FDA determination, but it is the first formal signal that something is wrong. A warning letter is the escalation: the FDA has decided the problems are serious enough to put on the public record. Warning letters are posted publicly and searchable in the FDA warning letters database. A warning letter naming the facility that makes your drug is a sell signal, not a hold signal.

Step 4: Read the SEC filings for CMC disclosures

Companies rarely announce manufacturing problems in a press release. They bury them in the risk factors and management discussion of the 10-K and 10-Q. Search the filings for the words “manufacturing,” “inspection,” “Form 483,” “warning letter,” and “CMC.” If a pre-PDUFA company’s 10-Q has a new risk factor about an unresolved inspection, that is your answer before the FDA gives it to you. Read more on what to pull out of regulatory documents in the guide to reading FDA briefing documents.

Step 5: Watch for outsourced manufacturing

Many small biotechs do not make their own drug. They hire a contract manufacturing organization (CMO or CDMO) to run the process. That means the inspection is out of the company’s control. A biotech can have perfect data and a clean balance sheet, and still get a CRL because a third-party factory failed its inspection. This is a recurring problem in cell and gene therapy, where capacity is scarce and companies lean on contract plants. See the CAR-T manufacturing bottleneck explainer for how concentrated this risk is.

Step 6: Read the regulatory tea leaves

If the FDA extends a PDUFA date without citing new safety or efficacy concerns, manufacturing is usually the reason. The agency needs more time to review a remediation plan or reinspect a facility. A delay that comes with “the company submitted additional CMC information” is a manufacturing signal, not a neutral update.

The anchor case: Elevar’s third CRL

Elevar Therapeutics’ rivoceranib plus camrelizumab is the cleanest example of manufacturing killing an approvable drug. The combination posted a median overall survival of 23.8 months in first-line liver cancer, the longest reported in the setting, and the drug is already approved in China. The FDA still issued a third CRL in July 2026, on cGMP manufacturing deficiencies, with no efficacy or safety concerns raised. The science worked. The factory did not. Read the full Elevar third CRL breakdown.

Common mistakes

Buying the stock the day before the PDUFA date. You are betting on a coin flip with a 37% base rate of rejection, and you have not done the manufacturing homework that would have told you which way the coin is weighted.

Assuming “no AdCom” means “no risk.” The FDA skips advisory committees for clean efficacy data, but a skipped AdCom says nothing about the factory.

Assuming an already-approved drug is safe. Rivoceranib was approved in China and still got three US CRLs. A foreign approval does not clear a US manufacturing inspection.

Ignoring the CMO. If the drug is made by a third party you have never heard of, the inspection risk lives with that third party, and you need to look it up too.

Final checklist

• Classified the application: NDA (low manufacturing risk) or BLA (high)?
• Found the PAI result on the FDA Data Dashboard: NAI, VAI, or OAI?
• Searched for a Form 483 or warning letter on the facility?
• Checked the 10-K/10-Q risk factors for “manufacturing” and “inspection”?
• Identified who makes the drug, and checked that facility too?
• Flagged any PDUFA extension that cites CMC, not clinical, reasons?

Run this before you put money down. For the broader pre-PDUFA positioning framework, see how to trade FDA catalysts, and for what a rejection actually means, start with what a CRL is.